Immunocore (IMCR) Projected to Release Quarterly Earnings on Thursday

Immunocore (NASDAQ:IMCR) is expected to post its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect Immunocore to announce earnings of ($0.01) per share and revenue of $146.6880 million for the quarter. Individuals can find conference call details on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Monday, August 10, 2026 at 2:00 AM ET.

Immunocore (NASDAQ:IMCR) last posted its quarterly earnings data on Wednesday, May 6th. The company reported $0.25 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.51. The company had revenue of $106.68 million for the quarter, compared to the consensus estimate of $145.20 million. Immunocore had a negative net margin of 6.68% and a negative return on equity of 7.07%. The firm’s revenue was up 13.6% compared to the same quarter last year. During the same quarter last year, the firm posted $0.10 earnings per share. On average, analysts expect Immunocore to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Immunocore Stock Performance

Shares of NASDAQ IMCR opened at $33.42 on Thursday. The firm has a 50 day moving average of $31.01 and a 200 day moving average of $31.30. The company has a current ratio of 4.18, a quick ratio of 4.15 and a debt-to-equity ratio of 1.00. The firm has a market capitalization of $1.70 billion, a price-to-earnings ratio of -60.76 and a beta of 0.73. Immunocore has a 12-month low of $27.56 and a 12-month high of $40.71.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in IMCR. Orion Porfolio Solutions LLC grew its position in shares of Immunocore by 4.5% during the second quarter. Orion Porfolio Solutions LLC now owns 23,965 shares of the company’s stock valued at $752,000 after purchasing an additional 1,031 shares in the last quarter. Arax Advisory Partners lifted its position in shares of Immunocore by 302.9% in the fourth quarter. Arax Advisory Partners now owns 1,386 shares of the company’s stock worth $48,000 after buying an additional 1,042 shares in the last quarter. Osaic Holdings Inc. lifted its position in shares of Immunocore by 117.4% in the second quarter. Osaic Holdings Inc. now owns 3,148 shares of the company’s stock worth $97,000 after buying an additional 1,700 shares in the last quarter. Legal & General Group Plc boosted its stake in Immunocore by 2.0% during the third quarter. Legal & General Group Plc now owns 125,756 shares of the company’s stock valued at $4,562,000 after buying an additional 2,517 shares during the last quarter. Finally, Federation des caisses Desjardins du Quebec boosted its stake in Immunocore by 162.1% during the fourth quarter. Federation des caisses Desjardins du Quebec now owns 5,478 shares of the company’s stock valued at $190,000 after buying an additional 3,388 shares during the last quarter. Institutional investors own 84.50% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently weighed in on IMCR shares. Zacks Research cut shares of Immunocore from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 7th. Weiss Ratings reissued a “sell (e+)” rating on shares of Immunocore in a report on Friday, July 17th. HC Wainwright restated a “buy” rating and issued a $100.00 price target on shares of Immunocore in a research report on Monday, April 20th. Wall Street Zen cut Immunocore from a “buy” rating to a “hold” rating in a research report on Tuesday. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Immunocore in a research note on Monday, July 13th. Five equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Immunocore currently has a consensus rating of “Hold” and a consensus price target of $56.71.

Immunocore Company Profile

Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.